Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A DORIA

Showing results (321-330 of 667) with videos related to

Pageof 67
Sort By:
Science (New York, N.Y.)|February 27, 2016
Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibodyDavide Corti, John Misasi, Sabue Mulangu, et al.
Cell Reports|April 7, 2021
Fusion peptide priming reduces immune responses to HIV-1 envelope trimer baseAngela R Corrigan, Hongying Duan, Cheng Cheng, et al.
Cell Host & Microbe|March 4, 2021
B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodiesSamantha M Townsley, Gina C Donofrio, Ningbo Jian, et al.
Nature|September 5, 2014
Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interfaceJinghe Huang, Byong H Kang, Marie Pancera, et al.
Biorxiv : the Preprint Server for Biology|May 25, 2021
Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variantsAmarendra Pegu, Sarah O'Connell, Stephen D Schmidt, et al.
Immunity|May 8, 2025
Vaccination of nonhuman primates elicits a broadly neutralizing antibody lineage targeting a quaternary epitope on the HIV-1 Env trimerFabian-Alexander Schleich, Shridhar Bale, Javier Guenaga, et al.
Cell Reports|August 7, 2020
Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell SignatureCheng Cheng, Hongying Duan, Kai Xu, et al.
Cell Reports|December 15, 2024
A multidonor class of highly glycan-dependent HIV-1 gp120-gp41 interface-targeting broadly neutralizing antibodiesEvan M Cale, Chen-Hsiang Shen, Adam S Olia, et al.
Scientific Reports|February 22, 2020
Preclinical Development of a Fusion Peptide Conjugate as an HIV Vaccine ImmunogenLi Ou, Wing-Pui Kong, Gwo-Yu Chuang, et al.
The Journal of Clinical Investigation|March 18, 2020
Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral reboundEvan M Cale, Hongjun Bai, Meera Bose, et al.
Pageof 67

Showing results (321-330 of 667) with videos related to

Sort By:
Pageof 67
Science (New York, N.Y.)|February 27, 2016
Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibodyDavide Corti, John Misasi, Sabue Mulangu, et al.
Cell Reports|April 7, 2021
Fusion peptide priming reduces immune responses to HIV-1 envelope trimer baseAngela R Corrigan, Hongying Duan, Cheng Cheng, et al.
Cell Host & Microbe|March 4, 2021
B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodiesSamantha M Townsley, Gina C Donofrio, Ningbo Jian, et al.
Nature|September 5, 2014
Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interfaceJinghe Huang, Byong H Kang, Marie Pancera, et al.
Biorxiv : the Preprint Server for Biology|May 25, 2021
Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variantsAmarendra Pegu, Sarah O'Connell, Stephen D Schmidt, et al.
Immunity|May 8, 2025
Vaccination of nonhuman primates elicits a broadly neutralizing antibody lineage targeting a quaternary epitope on the HIV-1 Env trimerFabian-Alexander Schleich, Shridhar Bale, Javier Guenaga, et al.
Cell Reports|August 7, 2020
Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell SignatureCheng Cheng, Hongying Duan, Kai Xu, et al.
Cell Reports|December 15, 2024
A multidonor class of highly glycan-dependent HIV-1 gp120-gp41 interface-targeting broadly neutralizing antibodiesEvan M Cale, Chen-Hsiang Shen, Adam S Olia, et al.
Scientific Reports|February 22, 2020
Preclinical Development of a Fusion Peptide Conjugate as an HIV Vaccine ImmunogenLi Ou, Wing-Pui Kong, Gwo-Yu Chuang, et al.
The Journal of Clinical Investigation|March 18, 2020
Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral reboundEvan M Cale, Hongjun Bai, Meera Bose, et al.
Pageof 67